Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;18(8):50.
doi: 10.1007/s11926-016-0601-0.

Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

Filipe C Araújo  1 , João Gonçalves  2 , João Eurico Fonseca  3   4
Affiliations
Review

Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?

Filipe C Araújo et al. Curr Rheumatol Rep. 2016 Aug.

Abstract

Despite representing a breakthrough in the treatment of immune-mediated rheumatic diseases, the direct costs of biotechnological therapies represent a burden to healthcare budgets worldwide. Furthermore, several studies demonstrated that socioeconomically constrained countries have poorer access to these therapies and this has consequences on the optimal management of rheumatic patients. Experience with small peptide biosimilars like filgrastim and epoetin confirmed significant cost savings but revealed variable market uptake. In this report, we summarize the available budget impact models and discuss possible determinants of the pharmacoeconomic performance of antirheumatic biosimilar drugs.

Keywords: Antirheumatic agents; Biosimilars; CT-P13; Pharmacoeconomics; Rheumatoid arthritis.

PubMed Disclaimer

References

    1. Eur J Health Econ. 2014 May;15 Suppl 1:S65-71 - PubMed
    1. Ann Rheum Dis. 2009 Nov;68(11):1666-72 - PubMed
    1. Adv Ther. 2015 Aug;32(8):742-56 - PubMed
    1. PLoS One. 2014 May 08;9(5):e97077 - PubMed
    1. Nat Biotechnol. 2010 Jan;28(1):28-31 - PubMed

MeSH terms

Substances

LinkOut - more resources